Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Tracking error happens when a fund deviates from its index due to replication method, fees, or liquidity. Grasp the causes to improve tracking.
22,885 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Many investors stumble because they try to go all in. This article shows how starting small works: starter positions ...
When a small-cap tech company reports results that miss expectations, the stock often takes a hit. This piece dives i...
REX Shares unveils a broadened ETF lineup centered on income, leverage, crypto, and thematic strategies, aiming to me...
Salesforce surged Thursday as the company announced a major debt offering to back a sizable share repurchase plan. Th...
Even with about $1.1 billion flowing into Bitcoin ETFs, prices keep slipping. This article explains why inflows don’t...
CrowdStrike stock absolutely hammered this week, yet the dip isn’t a clear buy signal. I break down the risks, the gr...
The White House is proposing a 63% cut to the CDFI Fund for FY2027, raising questions about accountability vs. capaci...
Howard Lindzon explains that seed investing hinges on a power-law mindset: most bets fail, but one or two extraordina...
A high-flying semiconductor stock grabbed headlines as it soared. Yet one large investor chose to sell an $89 million...
Bitcoin still dominates headlines, but Ethereum’s evolving ecosystem and staking potential offer a compelling longer-...
As clean energy climbs, storage plays a pivotal role. This article breaks down why energy stock soaring today points ...